C4X Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.93
Previous CloseN/A
Volume0.00
Average Volume (3M)5.17K
Market Cap
€373.45M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume0
30 Day Avg. Volume5,166
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumA sustained revenue rebound (~+40.6% to ~2.6M in 2025) signals improving commercial traction of development programs and better R&D-to-revenue conversion. That trend reduces near-term funding pressure and supports scaling clinical activities, making future operational plans more durable.
High Gross MarginsConsistently strong gross margins (~67–71%) reflect a favorable cost structure for the company’s small-molecule oncology programs. High product-level margins provide structural leverage as revenue scales, improving the prospect of eventual sustainable profitability once fixed development costs are absorbed.
Positive Operating & Free Cash FlowOperating cash flow and free cash flow turned positive in 2025, indicating improved cash generation from core activities. This durable improvement extends runway, reduces immediate financing dependence and supports funding of clinical milestones, provided cash generation remains stable with controlled spending.
Bears Say
High LeverageElevated leverage (debt-to-equity ~3.7x) materially constrains financial flexibility and raises refinancing and interest-rate risks. For a clinical-stage biotech, high debt increases the probability of dilutive capital raises or restrictive covenants if development timelines slip, weakening long-term resilience.
Persistent Net LossesDespite revenue and cash-flow gains, the company reported a -4.9M net loss in 2025. Continued negative net income underscores reliance on successful clinical outcomes or external funding to reach durable profitability and heightens execution risk across the multi-year development cycle.
Balance-sheet Volatility & Small ScaleSharp swings in equity and shrinking total assets highlight capitalization volatility and small scale. Limited asset base and few employees magnify the impact of trial setbacks or funding gaps, increasing the chance of disruptive financing events that can alter strategy or dilute shareholders.
C4X FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.93 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €373.45M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in DE:C4X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―